These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36549559)

  • 1. Systematic evaluation of the effect of different apolipoprotein A-I mimetic peptides on the performance of synthetic high-density lipoproteins in vitro and in vivo.
    Yuan W; Ernst K; Kuai R; Morin EE; Yu M; Sviridov DO; Tang J; Mei L; Li D; Ackermann R; Remaley AT; Schwendeman A
    Nanomedicine; 2023 Feb; 48():102646. PubMed ID: 36549559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.
    Li D; Fawaz MV; Morin EE; Ming R; Sviridov D; Tang J; Ackermann R; Olsen K; Remaley AT; Schwendeman A
    Mol Pharm; 2018 Jan; 15(1):83-96. PubMed ID: 29141139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly.
    Patel H; Ding B; Ernst K; Shen L; Yuan W; Tang J; Drake LR; Kang J; Li Y; Chen Z; Schwendeman A
    Int J Nanomedicine; 2019; 14():3069-3086. PubMed ID: 31118623
    [No Abstract]   [Full Text] [Related]  

  • 4. Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.
    Fawaz MV; Kim SY; Li D; Ming R; Xia Z; Olsen K; Pogozheva ID; Tesmer JJG; Schwendeman A
    J Pharmacol Exp Ther; 2020 Feb; 372(2):193-204. PubMed ID: 31776208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
    Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
    J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization.
    Tang J; Li D; Drake L; Yuan W; Deschaine S; Morin EE; Ackermann R; Olsen K; Smith DE; Schwendeman A
    J Lipid Res; 2017 Jan; 58(1):124-136. PubMed ID: 27881716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.
    Ditiatkovski M; Palsson J; Chin-Dusting J; Remaley AT; Sviridov D
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1301-1306. PubMed ID: 28522696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.
    D'Souza W; Stonik JA; Murphy A; Demosky SJ; Sethi AA; Moore XL; Chin-Dusting J; Remaley AT; Sviridov D
    Circ Res; 2010 Jul; 107(2):217-27. PubMed ID: 20508181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An apoA-I mimetic peptibody generates HDL-like particles and increases alpha-1 HDL subfraction in mice.
    Lu SC; Atangan L; Won Kim K; Chen MM; Komorowski R; Chu C; Han J; Hu S; Gu W; Véniant M; Wang M
    J Lipid Res; 2012 Apr; 53(4):643-52. PubMed ID: 22287724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
    Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
    J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.
    Osei-Hwedieh DO; Amar M; Sviridov D; Remaley AT
    Pharmacol Ther; 2011 Apr; 130(1):83-91. PubMed ID: 21172387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
    Wool GD; Reardon CA; Getz GS
    J Lipid Res; 2008 Jun; 49(6):1268-83. PubMed ID: 18323574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of Lipid-Free and Lipid-Associated ApoA-I in Cellular Cho-lesterol Efflux.
    Dergunov AD; Garaeva EA; Savushkin EV; Litvinov DY
    Curr Protein Pept Sci; 2017; 18(1):92-99. PubMed ID: 27412400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the surface lipid composition of reconstituted LPA-I on apolipoprotein A-I structure and lecithin: cholesterol acyltransferase activity.
    Sparks DL; Frank PG; Neville TA
    Biochim Biophys Acta; 1998 Feb; 1390(2):160-72. PubMed ID: 9507105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of individual amino acids of apolipoprotein A-I in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements.
    Cho KH; Durbin DM; Jonas A
    J Lipid Res; 2001 Mar; 42(3):379-89. PubMed ID: 11254750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
    Carballo-Jane E; Chen Z; O'Neill E; Wang J; Burton C; Chang CH; Chen X; Eveland S; Frantz-Wattley B; Gagen K; Hubbard B; Ichetovkin M; Luell S; Meurer R; Song X; Strack A; Langella A; Cianetti S; Rech F; Capitò E; Bufali S; Veneziano M; Verdirame M; Bonelli F; Monteagudo E; Pessi A; Ingenito R; Bianchi E
    Bioorg Med Chem; 2010 Dec; 18(24):8669-78. PubMed ID: 21115285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.
    Ditiatkovski M; D'Souza W; Kesani R; Chin-Dusting J; de Haan JB; Remaley A; Sviridov D
    PLoS One; 2013; 8(7):e68802. PubMed ID: 23874769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
    Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
    Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1.
    Xie Q; Zhao SP; Li F
    Tohoku J Exp Med; 2010 Mar; 220(3):223-8. PubMed ID: 20208418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.